Ex-OpenAI executive Kevin Weil raises $215M to automate drug discovery

From OpenAI to the Lab

Kevin Weil is launching a new venture called Warp Sciences after leaving his role at OpenAI. At OpenAI, Weil served as chief product officer for major tools like ChatGPT and Codex before leading the company's science unit. He was responsible for developing models trained on chemistry, genomics, and protein engineering.

Weil departed OpenAI earlier this year after the company integrated its dedicated science unit into its broader product and model teams. His new company represents a more commercial and focused version of his previous work. Instead of general scientific exploration, Warp Sciences targets the specific process of testing chemical variants to reduce drug side effects.

The startup has already secured $215 million in funding to begin its operations. This investment was led by Lightspeed Venture Partners and includes backing from IVP, Premji Invest, and Lux Capital. The funding round values the company at $865 million.

Solving the Drug Bottleneck

Drug development is currently one of the most expensive and slowest industrial processes in the world. Moving a drug candidate from the discovery phase to human trials can take many years and cost hundreds of millions of dollars. A major bottleneck in this process is testing hundreds or thousands of variants of a single molecule.

Traditionally, this work has been handled by specialized contract research organizations, many of which are located in China. However, geopolitical tensions and concerns over intellectual property have created a growing demand for domestic alternatives. Warp Sciences intends to fill this gap by building a next-generation preclinical research organization in the United States.

The company's goal is to make the path from a promising molecule to a tested candidate shorter and more reliable. By creating a domestic provider, Warp Sciences hopes to provide a secure and faster way for pharmaceutical companies to develop new medicines.

How the AI Lab Works

Warp Sciences plans to combine artificial intelligence with automated laboratory systems. The company will use robotics to produce and test large numbers of molecule variants more quickly than traditional human-led methods. This approach is designed to bring frontier AI capabilities into a physical laboratory setting.

A key part of the strategy is the type of data used to train the models. While many AI models are trained on published literature, Warp's thesis is that models trained on real experimental feedback can be more effective. The laboratory will generate this data to help the AI propose and evaluate new variants in real time.

Weil described his goal as an attempt to bring AI "out of the browser and into the lab." By combining robotic hardware with experimental data, the company aims to create a system that can iterate on chemical structures with high speed and precision.

A Team of Specialists

The startup is led by a team with deep experience in both high-level AI and the life sciences. Co-founders include Manohar Paluri, a former Meta AI leader, and DJ Patil, who served as the first chief data scientist of the United States. Solomon Reisberg, formerly of Terremoto Biosciences, is also a co-founder.

The investor group includes several of Weil's former colleagues from OpenAI. Other notable backers include executives and founders from major technology companies such as Coinbase, Palantir, and LinkedIn. This mix of capital and expertise suggests a high level of confidence in the company's specialized approach.

Warp Sciences is still in its early stages and has not yet released public results or technical papers. However, the company has a clear problem statement and the necessary funding to build the physical infrastructure required for its laboratory operations.

The Path Forward

The success of Warp Sciences will depend on several technical and commercial factors. The company must ensure the quality of its laboratory data and the reliability of its robotic systems. It also needs to convince pharmaceutical companies to entrust their critical research to a new domestic provider.

Weil's move reflects a broader pattern of AI researchers moving from large model companies to solve narrow, high-value problems. While language and image generation have seen rapid progress, translating research models into reliable industrial tools for medicine has been slower. Warp Sciences is an attempt to close that translation gap.

The $215 million in funding provides the company with a substantial runway to build its physical labs. The real measure of success will come from the data the laboratory produces as it begins to test new molecules. The company aims to turn years of AI experience into a tool for making drug discovery more efficient.